Anti-LRPAP1 Magnetic Beads-IP Kit Product Components
| Components | Storage |
| Anti-LRPAP1 Magnetic Beads1,3 | 2-8℃ for 12 months |
| NP40 Cell Lysis Buffer2 | -20℃ for 12 months |
| 5×TBST（pH7.4） | |
| 1×TBST（pH7.4） | |
| ddH2O | |
| CD166 Positive Cell Lysate | -20℃ for 12 months |
| Alkaline Elution Buffer | 2-8℃ for 12 months |
| Acidity Elution Buffer | 2-8℃ for 12 months |
| Neutralization Buffer | 2-8℃ for 12 months |
[1] The IP KIT contains anti-LRPAP1 magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).
[2] Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.
[3] Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.
Anti-LRPAP1 Magnetic Beads-IP Kit Product Description
The Anti-LRPAP1 magnetic Beads, conjugated with Anti-LRPAP1 antibody, are used for immuneprecipitation (IP) of LRPAP1 proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing LRPAP1 proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound LRPAP1 proteins are dissociated from the magnetic beads using an elution buffer. Anti-LRPAP1 Magnetic Beads-IP Kit Antibody Information
Immunogen
Recombinant Mouse LRPAP1 protein (Catalog#50281-M08H)
Species Reactivity
Mouse Acetylcholinesterase / A
Source
Polyclonal Mouse Rabbit IgG
Preparation
Produced in rabbits immunized with purified, recombinant Mouse Acetylcholinesterase / ACHE (rM Acetylcholinesterase / ACHE; Catalog#50543-M08H; NP_033729.1; Met 1-Leu 614). Acetylcholinesterase / ACHE specific IgG was purified by Mouse Acetylcholinesterase / ACHE affinity chromatography.
Applications
Immunoprecipitation (IP), Minimum Protein Purification
Anti-LRPAP1 Magnetic Beads Immunoprecipitation (IP) Kit Alternative Names
Anti-AA617339ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-AI790446ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-AU042172ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-C77774ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-HBP44ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-RAPALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit
LRPAP1 Background Information
Receptor-associated protein (RAP) is a molecular chaperone for low density lipoprotein receptor-related protein (LRP), which plays a key role in cholesterol metabolism. The lipoprotein receptor-related protein (LRP) is an endocytic receptor for several ligands, such as alpha2-macroglobulin (alpha2 M) and apolipoprotein E. LRP is involved in the clearance of lipids from the bloodstream and is expressed in the atherosclerotic plaque. The LRP-associated protein (LRPAP in humans, RAP in mice) acts as a chaperone protein, stabilizing the nascent LRP peptide in the endoplasmic reticulum and Golgi complex. Alpha-2-macroglobulin receptor-associated protein, also known as low density lipoprotein receptor-related protein-associated protein 1, RAP and LRPAP1, is a 39 kDa protein and a member of the alpha-2-MRAP family. It is a receptor antagonist that interacts with several members of the low density lipoprotein (LDL) receptor gene family. Upon binding to these receptors, LRPAP1 inhibits all ligand interactions with the receptors. LRPAP1 is present on cell surface forming a complex with the alpha-2-macroglobulin receptor heavy and light chains. It binds with LRP1B and the binding is followed by internalization and degradation. LRPAP1 interacts with LRP1/alpha-2-macroglobulin receptor and LRP2 (previously called glycoprotein 33), and may be involved in the pathogenesis of membrane glomerular nephritis. LRPAP1 together with LRP2 forms the Heymann nephritis antigenic complex. LRP2 is expressed in epithelial cells of the thyroid, where it can serve as a receptor for the protein thyroglobulin. Intron 5 insertion/deletion polymorphism of RAP gene (LRPAP1) has been implicated in other diseases sharing etiology with gallstone disease (GSD). The LRPAP1 insertion/deletion polymorphism influences cholesterol homeostasis and may confer risk for gallstone disease and gallbladder carcinoma (GBC) incidence usually parallels with the prevalence of cholelithiosis. The genetic variations at the LRPAP1 locus may modulate Alzheimer disease (AD) phenotype beyond risk for disease. In addition, the variation at the LRPAP1 gene could contribute to the risk of developing an early episode of myocardial infarction (MI).
Full Name
low density lipoprotein receptor-related protein associated protein 1
References
Gonzlez P, et al. (2002) Variation in the lipoprotein receptor-related protein, alpha2-macroglobulin and lipoprotein receptor-associated protein genes in relation to plasma lipid levels and risk of early myocardial infarction. Coron Artery Dis. 13(5): 251-4. Schutte DL, et al. (2003) A LRPAP1 intronic insertion/deletion polymorphism and phenotypic variability in Alzheimer disease. Res Theory Nurs Pract. 17(4): 301-19? Pandey SN, et al. (2006) Lipoprotein receptor associated protein (LRPAP1) insertion/deletion polymorphism: association with gallbladder cancer susceptibility. Int J Gastrointest Cancer. 37(4): 124-8. Dixit M, et al. (2006) Association of low density lipoprotein receptor related protein-associated protein (LRPAP1) gene insertion/deletion polymorphism with gallstone disease.J Gastroenterol Hepatol. 21(5): 847-9.
新浪微博
腾讯微博
QQ空间
客服
